CliniQuantum
Majority stake in quantum-enabled clinical analytics
Visit QliniQuantum
54%
of CliniQuantum Ltd. ownership stake
Neurothera Labs holds approximately 54% of CliniQuantum Ltd., an Israeli company building quantum tools for clinical trial analysis.
improving
precision
CliniQuantum’s objective is to improve the precision of clinical trial outcomes by identifying patient subpopulations that respond to investigational therapies.
Our Aim
For Neurothera, that capability is intended to complement CNS drug development - including programs such as SCI-110 and SCI-210 - by supporting smarter study design and more precise analysis of complex trial datasets.
The aim is simple: find which patients respond to a treatment, and make trials more precise.
What it does?
CliniQuantum uses quantum simulation and quantum Monte Carlo methods to analyze clinical data. The platform is designed to:
spot responder groups that standard averages can miss
support smarter trial design
improve how complex CNS study data is read
Why it matters to Neurothera
Why It Matters
It sits alongside our drug programs, including SCI-110 and SCI-210. Better analysis of trial data can help us design studies more carefully and read results more clearly.
Milestone
Collaboration in the Neuroplastogens-based
In July 2026 Neurothera reported an end-to-end hybrid quantum-classical workflow on real clinical data - from data intake, through analysis, to interpretable results.